Home » Stocks » NVRO

Nevro Corp. (NVRO)

Stock Price: $151.12 USD -4.58 (-2.94%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 5.23B
Revenue (ttm) 362.05M
Net Income (ttm) -83.07M
Shares Out 33.68M
EPS (ttm) -2.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $151.12
Previous Close $155.70
Change ($) -4.58
Change (%) -2.94%
Day's Open 157.14
Day's Range 146.66 - 158.50
Day's Volume 588,045
52-Week Range 65.05 - 188.14

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Nevro's (NVRO) domestic and international revenues fell on a year-over-year basis in the fourth quarter.

Benzinga - 1 week ago

Shares of Nevro (NYSE:NVRO) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 52.27% year over year to ($0.21), which be...

PRNewsWire - 1 week ago

REDWOOD CITY, Calif., Feb. 24, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...

Zacks Investment Research - 2 weeks ago

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 1 month ago

REDWOOD CITY, Calif., Jan. 27, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...

PRNewsWire - 1 month ago

REDWOOD CITY, Calif., Jan. 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...

Kiplinger - 1 month ago

If you desire growth, then your sights should be set on small-cap stocks. These 11 have attracted the gaze of dozens of Wall Street's best minds.

Other stocks mentioned: BJ, FATE, GLNG, GTLS, HCAT, IIVI, LPSN, PDCE, PZZA, QTS
Zacks Investment Research - 1 month ago

Nevro's (NVRO) preliminary worldwide Q4 revenues are expected to decline from the year-ago quarter's figure.

Zacks Investment Research - 2 months ago

Nevro's (NVRO) submission of a pre-market approval supplement to the FDA to seek approval for its Senza System can help in the treatment of chronic pain associated with PDN.

PRNewsWire - 2 months ago

REDWOOD CITY, Calif., Dec. 28, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...

PRNewsWire - 2 months ago

REDWOOD CITY, Calif., Dec. 22, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...

Seeking Alpha - 2 months ago

Nevro has been prospering in its chosen specialty of opioid-free pain relief. Nevro's Omnia launch has been dampened by the pandemic; expect good things as the pandemic moves to the rear.

PRNewsWire - 2 months ago

REDWOOD CITY, Calif., Dec. 15, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...

PRNewsWire - 2 months ago

MARLBOROUGH, Mass., Dec. 14, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that a stipulation of dismissal has been filed in the Nevro Corporation (NYSE: NVRO)...

Other stocks mentioned: BSX
PRNewsWire - 2 months ago

REDWOOD CITY, Calif., Dec. 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...

Zacks Investment Research - 2 months ago

Investors grew bullish on Nevro's (NVRO) prospects, courtesy of the stock's solid prospects.

Zacks Investment Research - 3 months ago

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 3 months ago

REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...

PRNewsWire - 3 months ago

REDWOOD CITY, Calif., Nov. 24, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...

PRNewsWire - 3 months ago

REDWOOD CITY, Calif., Nov. 17, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...

Zacks Investment Research - 3 months ago

Nevro's (NVRO) domestic and international revenues increased on a year-over-year basis in the third quarter.

Seeking Alpha - 3 months ago

Nevro Corp. (NVRO) CEO Keith Grossman on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Nevro (NVRO) delivered earnings and revenue surprises of 50.85% and 4.17%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 4 months ago

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 4 months ago

Nevro (NVRO) continues to gain traction from its flagship platform, Senza, and R&D capabilities. However, stiff competition remains a woe.

Zacks Investment Research - 5 months ago

Nevro (NVRO) commences plan for manufacturing operations in Costa Rica, thereby expanding its geographic footprint and boosting growth prospects.

PRNewsWire - 5 months ago

REDWOOD CITY, Calif., Sept. 14, 2020 /PRNewswire/ -- Nevro Corp.

Zacks Investment Research - 6 months ago

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 6 months ago

REDWOOD CITY, Calif., Sept. 1, 2020 /PRNewswire/ -- Nevro Corp.

Investors Business Daily - 6 months ago

A Relative Strength Rating upgrade for Nevro shows improving technical performance.

Zacks Investment Research - 7 months ago

Nevro's (NVRO) domestic and international revenues declined on a year-over-year basis in Q2.

PRNewsWire - 7 months ago

REDWOOD CITY, Calif., Aug. 7, 2020 /PRNewswire/ -- Nevro Corp.

Seeking Alpha - 7 months ago

Nevro Corp (NVRO) CEO Keith Grossman on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Nevro (NVRO) delivered earnings and revenue surprises of 26.67% and 36.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 7 months ago

Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 7 months ago

REDWOOD CITY, Calif., July 20, 2020 /PRNewswire/ -- Nevro Corp.

Zacks Investment Research - 9 months ago

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 9 months ago

REDWOOD CITY, Calif., June 4, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic...

Zacks Investment Research - 9 months ago

Nevro (NVRO) received CE mark approval for the Senza Omnia SCS system, which is likely to boost its international presence.

PRNewsWire - 9 months ago

REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic...

Zacks Investment Research - 10 months ago

Nevro's (NVRO) domestic revenues improved on a year-over-year basis in Q1.

Seeking Alpha - 10 months ago

Nevro Corp (NVRO) CEO Keith Grossman on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Nevro (NVRO) delivered earnings and revenue surprises of 24.27% and 0.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 11 months ago

Nevro (NVRO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Investment Research - 11 months ago

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?

InvestorPlace - 11 months ago

Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.

Other stocks mentioned: ARCT, AUPH, CCXI, KDMN, NVAX, TMO
Zacks Investment Research - 11 months ago

Nevro (NVRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 1 year ago

Nevro (NVRO) sees strong segmental contributions in Q4.

Seeking Alpha - 1 year ago

Nevro Corp (NVRO) CEO Keith Grossman on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Nevro (NVRO) delivered earnings and revenue surprises of 29.03% and 3.20%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

About NVRO

Nevro, a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and ... [Read more...]

Industry
Medical Devices
IPO Date
Nov 6, 2014
CEO
D.Keith Grossman
Employees
843
Stock Exchange
NYSE
Ticker Symbol
NVRO
Full Company Profile

Financial Performance

In 2020, Nevro Corp.'s revenue was $362.05 million, a decrease of -7.23% compared to the previous year's $390.26 million. Losses were -$83.07 million, -19.89% less than in 2019.

Financial Statements

Analyst Forecasts

According to 15 analysts, the average rating for Nevro Corp. stock is "Buy." The 12-month stock price forecast is 199.50, which is an increase of 32.01% from the latest price.

Price Target
$199.50
(32.01% upside)
Analyst Consensus: Buy